HHS withdraws 340B drug rebate pilot program

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31.

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

Pressed by Sen. Bernie Sanders (I-VT), NIH Director Jay Bhattacharya acknowledged that he is not aware of any study pointing to a causal link between vaccines and autism.

White House launches TrumpRx website

TrumpRx, a direct-to-consumer drug purchasing platform, limited to self-pay patients, is live, as of Feb. 5.

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several aggressive cuts the White House had proposed for NIH.

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Sometime next week, the Senate is expected to vote on a legislative package that would determine the fiscal year 2026 spending levels for much of the federal government. xxx:moreReaders of The Cancer Letter may be breathing a sigh of relief that NIH seems like

Federal judge orders temporary block on 340B drug rebate pilot program

A federal judge has blocked the Health Resources and Services Administration from rolling out a pilot program that would reimburse safety net hospitals that get a discount on drugs through the 340B program via a rebate, as opposed to the status quo of up-front savings. The preliminary injunction was issued on Dec. 29, just a few days before the program was slated to begin on Jan 1.

January 09, 2026

Vol.52 No.1

By Sara Willa Ernst

HHS withdraws 340B drug rebate pilot program

YOU MAY BE INTERESTED IN

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

White House launches TrumpRx website

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Federal judge orders temporary block on 340B drug rebate pilot program

Renew today!

Subscriber content

Never miss an issue!

Login

HHS withdraws 340B drug rebate pilot program

YOU MAY BE INTERESTED IN

After a brief government shutdown, FY26 funding bill is signed into lawNIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

White House launches TrumpRx website

Spending bill passed by the House gives NIH $415M raise, NCI gets $128MLegislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Federal judge orders temporary block on 340B drug rebate pilot program

Never miss an issue!

Login

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched